The grim prognosis for patients diagnosed with malignant gliomas necessitates the
development of new therapeutic strategies for localized and sustained drug delivery to …

To date, the clinical outcomes and survival rates for patients with glioblastoma (GB) remain
poor. A promising approach to disease‐modification involves local delivery of adjuvant …

Despite advances in neuro-imaging, neurosurgery, radiation therapy, and chemotherapy,
limited progress has been made in the treatment of patients with high-grade astrocytomas …

The blood brain barrier (BBB) and the systemic toxicity of conventional chemotherapy
present obstacles to the success of future blood-borne drug therapies of brain tumors. The …

Glioblastoma multiforme (GBM) is the most aggressive brain tumor with median patient
survival of 12–15 months. To facilitate treatment development, bioengineered GBM models …

Glioblastoma multiforme (GBM) is the most aggressive, malignant brain tumor found in
adults, and has a short median survival time (MST). GBM is a heterogeneous group of brain …

Purpose: Carboplatin has shown promise experimentally as an antineoplastic agent against
both primary central nervous system (CNS) tumors and several solid tumors that frequently …

Objective: Glioblastoma multiforme (GBM) is the most common and most aggressive
malignant primary brain tumor in humans. The only interstitial chemotherapy pharmaceutical …

Despite intensive surgical excision, radiation therapy, and chemotherapy, the current life
expectancy for patients diagnosed with glioblastoma multiforme is only 12 to 15 months …

Malignant gliomas are among the most devastating human cancers. The infiltrating nature of
these malignancies makes complete surgical resection nearly impossible. Conventional …